Full-body scans: which startup is ahead?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
Neko Health is ahead overall in full-body scans today, while Prenuvo remains the clear leader in dedicated whole-body MRI and Function Health/Ezra is the strongest challenger.
The market has split into two different leadership models. Prenuvo has built the largest specialized MRI operation, while Neko has created a cheaper, faster preventive checkup that customers appear willing to repeat every year.
Prenuvo still has the largest verified examination base, with more than 170,000 completed scans. Neko has passed 100,000 examinations, leaving both companies far ahead of competitors that disclose only memberships, locations or vague customer totals.
Neko currently has the strongest momentum. Its average monthly examination volume appears to have increased more than elevenfold, and 75% of members now book and prepay for their next visit before leaving the clinic.
Price explains much of the competitive gap. Neko charges £299 for a broad non-MRI assessment, Function/Ezra offers an entry-level MRI to members for $899, and Prenuvo’s complete whole-body product costs $2,499.
Prenuvo provides the strongest standardized view of internal anatomy and has produced the deepest company-specific clinical research. The research is promising, but it still does not prove that routine MRI screening helps average-risk people live longer.
Function/Ezra has the widest MRI distribution, with more than 170 partner imaging locations and access to Function’s large preventive-health membership. What it has not shown is how many members actually purchase a scan or return for another one.
The hardest advantage to copy may belong to Neko. It controls its cameras, sensors, software and clinics, whereas most MRI competitors rely at least partly on equipment and infrastructure that hospitals or radiology chains already possess.
Prenuvo appears to have converted funding into completed examinations more efficiently so far. Neko has raised far more capital, although much of its latest financing is intended for expansion that has not happened yet.
The ranking could still change quickly. Function could enter the top two by publishing strong scan-conversion and retention figures, Prenuvo could regain the overall lead through lower prices or stronger outcome evidence, and Neko must prove that its clinic model travels successfully beyond Europe.
For now, Neko ranks first because it combines growth, repeat demand, affordability, proprietary technology and substantial expansion capital. Prenuvo is a close second with greater MRI depth, higher examination volume and stronger clinical infrastructure, while Function/Ezra ranks third on potential rather than demonstrated imaging scale.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Which full-body scan startups actually belong in this comparison?
The serious full-body scan startup field currently includes Neko Health, Prenuvo, Function Health through Ezra, Q Bio, Biograph and OneMRI.
These companies compete for the same basic customer: someone willing to pay privately for a broad health assessment before symptoms appear. Their products remain quite different. Prenuvo, Function/Ezra, Q Bio, Biograph and OneMRI place MRI at the center of the examination. Neko uses proprietary cameras, cardiovascular sensors, blood tests and other measurements without performing an MRI. Neko still belongs in the comparison because customers frequently choose between its £299 body scan and a more expensive whole-body MRI.
Ezra has been part of Function Health since Function acquired the company in 2025. We therefore treat Function/Ezra as one competitor. Function brings a large preventive-health membership, while Ezra supplies the imaging technology and partner network. (PR Newswire)
We exclude traditional radiology groups, hospital screening departments and older executive-health providers. We also exclude Fountain Life, Human Longevity and Echelon Health because full-body scanning forms one part of a much broader concierge service rather than the core product. Biograph remains in scope because its business is still young, independently funded and built almost entirely around advanced preventive testing.
Funding figures for private startups are uneven. Company announcements provide strong numbers for Neko and Function, while Prenuvo’s cumulative total comes from management disclosures. Biograph declined to disclose its funding when it emerged from stealth, although PitchBook data later reported by SFGATE placed the total at $53.9 million. (Neko Health)
| Startup | What the company currently sells | Disclosed cumulative funding |
|---|---|---|
| Neko Health | One-hour skin, cardiovascular, blood and metabolic assessment with a same-visit clinician consultation | About $1.025B, including a $65M Series A, $260M Series B and $700M Series C (TechCrunch) |
| Function Health / Ezra | MRI and CT scans connected to Function’s recurring laboratory-testing membership | About $350M raised by Function; Ezra had raised about $43M before the acquisition (HLTH) |
| Prenuvo | Head-to-ankle whole-body MRI, blood panels and clinical review | About $250M according to Prenuvo management (New York Post) |
| Q Bio | Whole-body MRI, biomarkers, genetics, wearable data and physician review | About $80M (Tracxn) |
| Biograph | Premium preventive-health membership combining MRI with 20 to 30-plus assessments | About $53.9M according to PitchBook data reported by SFGATE (SFGATE) |
| OneMRI | Partner-delivered whole-body MRI across Australia | A$2.5M seed round (OneMRI) |
Is anyone clearly ahead in full-body scans today?
The full-body scan market now has a clear top two: Prenuvo leads dedicated whole-body MRI, while Neko Health leads the broader preventive body-scan race.
Prenuvo has completed more MRI scans, runs a specialized radiology operation and offers the deepest standardized view of internal anatomy. Its current booking system says more than 170,000 people have used Prenuvo, while its affiliated radiology group includes more than 100 board-certified radiologists. No other startup has shown comparable MRI-specific volume. (Prenuvo)
Neko is moving faster as a consumer-health company. Its examination costs far less, most customers book another visit before leaving, and its latest financing gives it several times more capital than Prenuvo. Neko also controls the cameras, sensors, software and clinic experience, giving the company more freedom to improve its examination over time. (Neko Health)
Function/Ezra sits in third place today. The combined company offers lower-priced MRI through more than 170 partner locations and can market those scans to hundreds of thousands of Function members. Function has never disclosed how many members actually purchased an MRI, however, so its impressive distribution reach still lacks a matching scan-volume figure. (Ezra)
The structure is fairly clear. Prenuvo and Neko have separated from the field through real examination volume. Function has the strongest route into the leading group, while Q Bio, Biograph and OneMRI currently lead narrower niches.
If you want more recent data on this point, please see our latest longevity market report.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Which full-body scan startup has served the most people?
Prenuvo currently has the largest verified customer base in full-body MRI, with more than 170,000 completed scans.
Prenuvo had reported more than 150,000 scans at the beginning of 2026 and raised that figure above 170,000 when it launched its new membership a few months later. Those announcements imply that the company added at least 20,000 scans over roughly ten weeks, although the exact measurement dates may differ slightly from the publication dates. (Prenuvo)
Neko has completed more than 100,000 examinations in Sweden and the United Kingdom. That total already places Neko well above most preventive-health clinics, especially because the company operated from only eight physical locations before its American launch. (Neko Health)
Function says hundreds of thousands of people use its laboratory-testing membership. That number cannot be treated as imaging volume. Function members must separately buy an Ezra scan, and neither company currently reports the conversion rate.
Q Bio, Biograph and OneMRI have live products, although none has released a comparable cumulative customer count. Biograph told SFGATE that it had served thousands of customers without providing an exact total. OneMRI now offers scans through a large Australian partner network, but its booking footprint tells us more about availability than completed examinations. (SFGATE)
| Startup | Latest useful volume figure | What we can safely conclude |
|---|---|---|
| Prenuvo | More than 170,000 scans | Largest verified whole-body MRI customer base |
| Neko Health | More than 100,000 examinations | Second-largest verified preventive-scan base and the largest non-MRI operator |
| Function / Ezra | MRI volume undisclosed | Large membership and broad availability, with no public scan conversion rate |
| Biograph | Thousands of customers | Real premium demand, still far below the two leaders |
| Q Bio | Undisclosed | Commercially available, with little evidence of scale |
| OneMRI | Undisclosed | Rapid geographic availability across Australia, with completed volume unknown |
Which full-body scan startup is growing fastest now?
Neko Health is currently growing fastest, although Prenuvo’s recent MRI throughput is stronger than earlier evidence suggested.
Neko had completed 10,000 examinations by early 2025 and passed 100,000 around 18 months later. We calculate that Neko added roughly 90,000 examinations during that period, averaging close to 5,000 per month. The first 10,000 had taken nearly two years, equivalent to around 435 per month. On those rough averages, Neko increased its monthly throughput more than elevenfold. (Neko Health)
That acceleration came from opening more clinics rather than simply attracting more website registrations. Neko expanded from Stockholm and one London location into several London clinics, Manchester and Birmingham. Its latest Stockholm site also introduced upgraded Derma-2, Echo-2 and Spectrum-2 devices, which automate more of the examination and reduce the workload on clinical staff. (Neko Health)
Prenuvo also appears to be adding scans quickly. Its company updates moved from more than 150,000 completed scans to more than 170,000 over a short recent period. Prenuvo has therefore been adding customers at a pace that would have looked exceptional for this market only two years ago.
Function/Ezra may eventually expand faster because it uses existing MRI centers. The company has already grown its network beyond 170 locations, but availability and actual usage remain separate measures. Until Function publishes scan purchases, Neko has the clearest evidence of rapid growth.
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Which full-body scan company has the strongest proof that customers come back?
Neko Health has the best disclosed evidence of repeat demand in preventive body scanning.
In its latest update, Neko said 75% of members book and prepay for their next annual examination before leaving the clinic. The company had previously reported an 80% prebooking rate when it was much smaller. A five-percentage-point decline while examination volume rose tenfold suggests that repeat demand has stayed remarkably stable during expansion. (Neko Health)
Neko has also attracted more than 350,000 people to its waiting and registration pool. That represents around 3.5 interested customers for every person scanned so far. A waiting list can contain inactive or duplicated interest, so we give more weight to prepaid annual bookings. Still, the combination shows that Neko faces a capacity problem rather than a shortage of demand.
Prenuvo recently moved from one-off scans toward annual memberships that bundle MRI, laboratory tests and clinical reviews. That change should improve repeat usage, but Prenuvo has not released a renewal or annual rebooking rate. Its 170,000 completed scans prove substantial demand at a much higher price, even without a public retention number. (Prenuvo)
Function has hundreds of thousands of paying laboratory members, which creates an unusually large audience for MRI upselling. The company still needs to show how many members add a scan and how many repeat it. Until those numbers appear, Function’s membership cannot outweigh Neko’s prepaid renewal data.
If you want more recent data on this point, please see our latest longevity market report.
Who has made preventive body scanning affordable?
Neko Health has made broad preventive scanning cheapest, while Function/Ezra currently offers the lowest widely available MRI price among the larger competitors.
Neko charges £299 in the United Kingdom for a one-hour visit covering skin, heart, circulation, blood and metabolic health. That price sits far below the MRI services because Neko does not use an expensive MRI machine or radiologist for every customer. (Neko Health)
Function members currently pay $899 for its basic annual MRI, down from the public price of $999. Function membership itself costs $365 per year. The scan takes as little as 22 minutes and covers the head, neck, abdomen and pelvis. A $1,499 option adds the spine and lasts around 47 minutes. (Function Health)
Prenuvo charges $2,499 for either its full whole-body MRI membership or a standalone whole-body scan. Its lower $1,199 tier uses a more limited head-to-mid-thigh protocol and leaves out the arms, spine and aneurysm assessment. Prenuvo costs more because the complete examination covers a wider anatomical area and includes a more controlled clinical workflow. (Prenuvo)
The affordability ranking depends on what the customer wants. Neko wins for an annual broad health check. Function wins for entry-level MRI. Prenuvo offers a more complete MRI for customers willing to pay roughly three times Function’s entry price.
| Company and product | Current listed price | What the customer receives |
|---|---|---|
| Neko Health Scan | £299 | Skin, cardiovascular, blood and metabolic assessment; no MRI |
| Function/Ezra Annual MRI | $899 for Function members | Head, neck, abdomen and pelvis; up to 13 organs |
| Prenuvo Focused | $1,199 | Head-to-mid-thigh MRI and laboratory panel; spine and arms excluded |
| Prenuvo Comprehensive | $2,499 | Whole-body MRI, laboratory testing and follow-up review |
| OneMRI | A$2,990 | Whole-body MRI, radiologist report and doctor consultation (OneMRI) |
| Biograph Core | $7,500 | Whole-body MRI plus more than 20 other assessments (Biograph) |
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Which full-body scan company gives the most complete examination?
Prenuvo currently offers the strongest standardized whole-body MRI, while Biograph provides the broadest overall preventive-health workup.
Prenuvo’s full protocol covers the head, brain, major organs, spine and much of the musculoskeletal system down to the ankles. The scan uses multiple MRI sequences over approximately 50 to 60 minutes. Prenuvo then combines the imaging with laboratory tests and a provider review in its membership product. (Prenuvo)
Biograph goes wider across different types of testing. Its $7,500 Core membership combines whole-body MRI with a blood panel, genetic testing, DEXA body-composition imaging, VO₂ max testing and a physician-led review. The $15,000 Black tier adds coronary CT angiography, low-dose lung CT, a multi-cancer blood test, brain assessments, sleep testing and continuous glucose monitoring. (Biograph)
Q Bio has the most coherent multimodal design among the smaller companies. Its Q Exam brings together whole-body MRI, more than 120 blood biomarkers, 163 risk-related genes, wearable data, prior medical records and a 45-minute physician review. Q Bio also stores the results in a dashboard built for year-over-year comparison. The company’s limited clinic presence currently prevents that strong product design from becoming market leadership. (Q Bio)
Neko covers fewer internal structures than MRI. Its strengths are speed, affordability and repeated measurement of common cardiovascular, metabolic and skin risks. A healthy 35-year-old looking for an annual baseline may find Neko more useful than an expensive MRI, even though the examination is anatomically less detailed.
Biograph delivers the largest testing bundle, Prenuvo delivers the deepest standardized MRI, and Neko offers the most accessible recurring checkup. Those are three different kinds of completeness.
If you want more recent data on this point, please see our latest longevity market report.
Which full-body scan product is actually ready for routine paid use?
Prenuvo and Neko Health are the only full-body scan startups currently operating at proven six-figure examination scale.
Both companies already run standardized consumer services rather than pilots. Function/Ezra is also commercially available across more than 170 partner locations, but it has not disclosed enough scan volume to show comparable adoption. Q Bio, Biograph and OneMRI remain smaller or more specialized.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Which full-body scan company has the best clinical evidence?
Prenuvo has the deepest company-specific clinical evidence, yet the research still falls short of proving that routine whole-body MRI helps average-risk people live longer.
Prenuvo studied 1,011 people who received screening whole-body MRI and had approximately 12 months of follow-up. Tissue biopsies confirmed cancer in 2.2% of participants. The company estimated that 64% of detected cancers were localized and reported that 68% appeared in organs without established screening programs. Those results are promising, especially for kidney, bladder and lymphoma detection, although the retrospective study came from Prenuvo’s own clinical network. (Prenuvo)
Prenuvo has lately started using its much larger dataset for broader research. One recent analysis covered 118,019 scans performed across the United States and Canada, while another reviewed brain findings in 78,800 people. These datasets demonstrate scale and can improve reporting standards, but retrospective analyses of findings cannot answer whether population screening lowers mortality or healthcare spending. (Prenuvo)
Independent research remains cautious. A meta-analysis of ten studies covering more than 9,000 asymptomatic people found a pooled cancer-detection rate of 1.57%. The authors also found frequent incidental abnormalities, inconsistent protocols and little evidence about cost-effectiveness or long-term outcomes. (European Radiology)
The American College of Radiology still says there is insufficient evidence to recommend total-body MRI for people without symptoms, relevant risk factors or a suggestive family history. A more recent Radiological Society of North America review reached the same basic conclusion while acknowledging that commercial demand continues to grow rapidly. (American College of Radiology)
Neko’s evidence addresses a different question. The company followed 1,469 people who returned for a second examination and found improvements in blood pressure, cholesterol and blood sugar. The absence of a control group means we cannot determine how much came from Neko, medication changes, healthier behavior or the type of person who chooses to return. (Neko Health)
Prenuvo has produced the most substantial clinical dataset, Neko has encouraging longitudinal observations, and the other startups have disclosed very little outcome research. None has established a general medical case for annual scanning across the healthy population.
Which full-body scan company handles false positives best?
Prenuvo currently has the strongest system for sorting MRI findings, while Neko gives customers faster face-to-face explanation.
Prenuvo uses specialist radiologists and standardized risk categories. Neko reviews most results with a clinician during the same visit. No independent comparison has shown which service causes fewer unnecessary follow-up tests, so neither company has proved a clear clinical advantage here.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Who can bring full-body scans to the most cities?
Function/Ezra currently offers the widest MRI access through more than 170 partner locations.
Prenuvo has a smaller but more controlled network of dedicated and mobile sites. OneMRI uses a similar partner model across Australia, while Neko builds its own clinics and therefore expands more slowly. Function leads on availability, but Prenuvo offers greater consistency.
Which partnerships show real commercial strength in full-body scans?
Function has the strongest mass-distribution relationships, while Prenuvo has built the more medically credible partnerships.
Function connects laboratory access through more than 2,000 Quest Diagnostics locations with Ezra’s network of more than 170 imaging centers. That gives Function the broadest customer funnel, even though it still does not disclose how many members purchase scans. (Function Health)
Prenuvo works with primary-care providers such as Baker Health and Parsley Health, while John Hancock offers some customers discounted access. Those relationships help with referrals and follow-up but have not produced broad insurance reimbursement. (Prenuvo)
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
What can the leading full-body scan startups do that hospitals cannot easily copy?
Neko’s integrated hardware and clinic system is currently hardest to copy, while Prenuvo owns the strongest specialized whole-body MRI dataset.
Hospitals can already offer MRI scans, but they rarely combine standardized protocols, consumer-friendly reports, longitudinal comparisons and a smooth annual membership. Neko controls the sensors, software and clinic experience. Prenuvo has built expertise from more than 170,000 similar scans. Function controls the recurring health record while using outside laboratories and imaging centers.
The scan itself is widely available. Making the results consistent, understandable and useful enough that customers return is the real advantage.
If you want more recent data on this point, please see our latest longevity market report.
Which full-body scan startup is turning funding into real output most efficiently?
Prenuvo currently appears to have turned funding into completed scans more efficiently than Neko.
Prenuvo has raised about $250 million and completed more than 170,000 scans, equal to roughly $1,470 of funding per historical scan. Before its latest financing, Neko had raised about $325 million and completed more than 100,000 examinations, or approximately $3,250 per scan.
These ratios are rough and should not be mistaken for unit economics. Neko’s latest $700 million is intended to finance future expansion, while Prenuvo has already deployed most of its capital. Still, Prenuvo has produced more visible commercial output from a smaller funding base.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
Can hospitals and radiology chains catch up with the full-body scan startups?
Large radiology chains can catch up quickly on MRI availability, but matching the complete consumer experience will take longer.
Existing providers already own scanners and employ radiologists. Their weaker areas are usually online booking, standardized preventive protocols, readable reports, follow-up coordination and year-over-year comparison.
Prenuvo, Neko and Function have spent years building those layers. A major healthcare group combining existing imaging capacity with strong consumer software and trusted doctors would remain a serious threat.
What could change the full-body scan ranking?
Function/Ezra could break into the top two by publishing strong MRI conversion and repeat-purchase numbers.
Neko must now prove that its European clinic model works in the United States. Prenuvo could regain first place by lowering prices or producing stronger evidence that screening improves long-term outcomes. Q Bio remains the technical wildcard if its faster quantitative scanner reaches wider commercial deployment.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
Which full-body scan startups are actually ahead?
Neko Health is currently ahead overall, Prenuvo remains the clear whole-body MRI leader, and Function/Ezra is the only challenger close enough to change the top two quickly.
We place Neko first because the company combines rapid examination growth, unusually strong prepaid renewals, accessible pricing, proprietary hardware and enough capital to fund a serious international rollout. Neko’s main limitation is equally clear: its body scan cannot see internal anatomy with the depth of an MRI.
Prenuvo takes second place by a narrow margin. It has completed more scans, built the strongest radiology operation and produced the category’s deepest research base. Prenuvo loses the overall lead because its core product still costs $2,499 and remains difficult to justify as a routine annual purchase for most people.
Function/Ezra ranks third. Its 22-minute MRI, lower price, nationwide partner network and large Function membership give it enormous potential. We would move Function higher once the company shows how many members actually buy scans and return for another one.
The distance below the top three is wider. Q Bio has an excellent technical concept with limited commercial proof. Biograph leads the luxury end of the market but has little reason to chase mass volume. OneMRI is an impressive regional operator that remains early.
| Rank | Startup | Why it ranks here now |
|---|---|---|
| 1 | Neko Health | Best overall combination of growth, repeat demand, affordability, proprietary technology and current momentum. The product remains less anatomically detailed than MRI |
| 2 | Prenuvo | Largest dedicated whole-body MRI operator, strongest clinical infrastructure and deepest evidence base. High pricing keeps it just behind Neko overall |
| 3 | Function Health / Ezra | Widest MRI access, fastest entry-level scan and strongest built-in distribution. Public imaging-volume and retention data remain missing |
| 4 | Q Bio | Strongest quantitative and multimodal product vision among the smaller companies. Deployment and customer scale remain too limited |
| 5 | Biograph | Most complete premium preventive-health service, with excellent physician support. Its $7,500 to $15,000 model targets a small wealthy market |
| 6 | OneMRI | Broad Australian partner footprint and strong execution for a recently funded startup. Completed scan volume, clinical evidence and international reach remain limited |
If you want more recent data on this point, please see our latest longevity market report.
OUR METHODOLOGY
This analysis examines which full-body scan startup is currently ahead. Because leadership can mean examination volume, growth, affordability, repeat demand, clinical evidence, anatomical coverage or distribution, we assessed each of those dimensions separately before forming the final ranking.
We prioritized demonstrated customer behavior over theoretical reach. Completed paid examinations and prepaid annual rebookings received more weight than waiting lists, general health memberships, announced locations or the number of people a partner network could potentially serve.
We treated Prenuvo’s MRI scans, Neko’s sensor-based examinations and the broader testing packages offered by Q Bio and Biograph as competing preventive-health products rather than technically identical scans. The comparison focuses on the result offered to the customer, the price, the operating scale and the evidence that people use the service again.
Completed examination totals were used as the clearest measure of current adoption. Membership numbers were kept separate from scan volume because a Function Health member does not automatically become an Ezra imaging customer. Geographic availability was also separated from completed usage.
For growth, we compared disclosed cumulative examination figures across time and used them to calculate rough monthly throughput. These calculations show the direction and approximate scale of expansion, not audited monthly operating figures.
For clinical evidence, we distinguished between detecting abnormalities, improving intermediate health measurements and proving better long-term outcomes. Company studies were useful for assessing datasets and operational experience, while independent reviews and professional guidance were used to judge how far the medical case has actually progressed.
The final ranking is editorial rather than mechanical. We assessed the aggregate direction and strength of the available evidence, with more confidence in companies that disclose examination volume, repeat behavior and clinical operations than in companies whose position rests mainly on product ambition, funding or distribution potential.
Key sources include Neko Health’s latest funding, examination-volume and repeat-booking update, Neko Health’s report on returning members, Prenuvo’s scan-volume and membership announcement, Prenuvo’s whole-body MRI protocol, Prenuvo’s cancer-detection study, Function Health’s scan products and prices, the Function Health acquisition of Ezra, Q Bio’s examination protocol, Biograph’s membership products, OneMRI’s examination and pricing information, the American College of Radiology’s position on total-body MRI screening, and the independent systematic review and meta-analysis of whole-body MRI screening in asymptomatic people.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across Europe, Asia, North America, Africa, and South America in the longevity market
Related blog posts
- Which startup is ahead in longevity checkups?
- Who is emerging as the leader in preventive health?
- Which AI startup has the edge in medical imaging?
